



## EUROPEAN MIGRAINE WEBINAR SERIES

# Optimizing Patient Outcomes in Difficult-to-treat Migraine: What Do the Data Tell Us?

**Prof. Hans-Christoph Diener**

21 January 2021 | 18:30–19:15 CET

Hi there,

We are very pleased to invite you to the Teva Migraine Webinar titled “Optimizing Patient Outcomes in Difficult-to-treat Migraine: What Do the Data Tell Us?” During this presentation, Professor Hans-Christoph Diener will focus on the available clinical data supporting the use of anti-CGRP pathway monoclonal antibodies for the treatment of difficult-to-treat migraine.

All relevant information about this webinar and your speaker can be found below.

Click above to register!

## Webinar Details

**Prof. Hans-Christoph Diener**  
21 January 2021 | 18:30–19:15 CET



## Focus Objectives

- Understand contributing risk factors to difficult-to-treat migraine
- Review guidelines for therapy use in patients with difficult-to-treat migraine and inadequate response to several therapies
- Discuss clinical data of anti-CGRP therapies in patients with difficult-to-treat migraine

## About Your Speaker

**Prof. Hans-Christoph Diener**

Professor Hans-Christoph Diener is Emeritus Professor of Neurology at the Medical Faculty of the University of Duisburg-Essen in Essen, Germany and works at the Institute for Medical Informatics, Biometry and Epidemiology in Germany. Prof. Diener co-chairs the Guidelines Committee of the German Society of Neurology and the Clinical Trials Guidelines Committee of the International Headache Society (IHS). His previous positions include Chairman of the Department of Neurology at the University of Essen and President of the German Neurological Society, the European Headache Federation and the IHS. He has authored and co-authored over 989 articles in peer-reviewed journals, and wrote or edited 89 books. Prof. Diener serves as the editor of several journals, including deputy editor of *Cephalalgia*, and sits on the editorial board of *Lancet Neurology*. He has acted as a principal investigator in over 30 trials as his research interests are focused in headache and stroke.